Kaplan-Meier curves showing effect of NPM1 VAF within subpopulations defined by DNMT3A comutation. (A) Effect of high NPM1 VAF (n = 10) on EFS in DNTM3A-mutated patients (n = 55; 5.7 vs 37.4 months; P < .0001). (B) Effect of high NPM1 VAF (n = 14) on EFS in DNMT3A wild-type patients (n = 54; 11.0 months vs not reached; P = .04).